These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 30241190)
1. Unfortunate Accident or Blessing in Disguise? Dramatic Response to Incidental Intrathoracic Delivery of Anti-HER2 Regimen. Tariq K; Keen R; Draper K; Tang SC J Glob Oncol; 2018 Sep; 4():1-4. PubMed ID: 30241190 [No Abstract] [Full Text] [Related]
2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825 [TBL] [Abstract][Full Text] [Related]
3. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option]. Ito Y Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090 [No Abstract] [Full Text] [Related]
4. Nano-pharmaceutical formulations for targeted drug delivery against HER2 in breast cancer. Sadat SM; Saeidnia S; Nazarali AJ; Haddadi A Curr Cancer Drug Targets; 2015; 15(1):71-86. PubMed ID: 25564255 [TBL] [Abstract][Full Text] [Related]
6. The distinctive nature of HER2-positive breast cancers. Burstein HJ N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735 [No Abstract] [Full Text] [Related]
7. HER2 targeted therapy in breast cancer...beyond Herceptin. Pal SK; Pegram M Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385 [TBL] [Abstract][Full Text] [Related]
8. Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions. Smith IE Breast; 2009 Oct; 18 Suppl 3():S146-9. PubMed ID: 19914535 [No Abstract] [Full Text] [Related]
9. The challenge of selecting adjuvant breast cancer chemotherapy for older patients. Downey L Oncology (Williston Park); 2010 Jun; 24(7):621, 624. PubMed ID: 20669798 [No Abstract] [Full Text] [Related]
10. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. Reed SD; Schulman KA Value Health; 2009; 12(5):637-40. PubMed ID: 19473336 [No Abstract] [Full Text] [Related]
11. Neoadjuvant Therapy for HER2-positive Breast Cancer. Wuerstlein R; Harbeck N Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759 [TBL] [Abstract][Full Text] [Related]
12. Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here? Teplinsky E; Esteva FJ Curr Oncol Rep; 2015 Oct; 17(10):46. PubMed ID: 26314739 [TBL] [Abstract][Full Text] [Related]
13. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Cameron D Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920 [No Abstract] [Full Text] [Related]
14. Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones. Hirte HW; Hotte SJ J Clin Oncol; 2008 Jul; 26(20):3301-2. PubMed ID: 18490647 [No Abstract] [Full Text] [Related]
17. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo. Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364 [TBL] [Abstract][Full Text] [Related]
18. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting. Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356 [TBL] [Abstract][Full Text] [Related]
19. Evolution of anti-HER2 therapies for cancer treatment. Parakh S; Gan HK; Parslow AC; Burvenich IJG; Burgess AW; Scott AM Cancer Treat Rev; 2017 Sep; 59():1-21. PubMed ID: 28715775 [TBL] [Abstract][Full Text] [Related]
20. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]